Virginia Meca-Lallana , Laura Esparcia-Pinedo , Clara Aguirre , Carolina Díaz-Pérez , Ainhoa Gutierrez-Cobos , Mónica Sobrado , Estefanía Carabajal , Beatriz del Río , Noelia Ropero , Ramón Villagrasa , José Vivancos , Francisco Sanchez-Madrid , Arantzazu Alfranca
{"title":"免疫调节药物治疗多发性硬化症患者接种SARS-CoV-2疫苗后体液免疫和细胞免疫分析","authors":"Virginia Meca-Lallana , Laura Esparcia-Pinedo , Clara Aguirre , Carolina Díaz-Pérez , Ainhoa Gutierrez-Cobos , Mónica Sobrado , Estefanía Carabajal , Beatriz del Río , Noelia Ropero , Ramón Villagrasa , José Vivancos , Francisco Sanchez-Madrid , Arantzazu Alfranca","doi":"10.1016/j.clicom.2023.02.001","DOIUrl":null,"url":null,"abstract":"<div><p>We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs\",\"authors\":\"Virginia Meca-Lallana , Laura Esparcia-Pinedo , Clara Aguirre , Carolina Díaz-Pérez , Ainhoa Gutierrez-Cobos , Mónica Sobrado , Estefanía Carabajal , Beatriz del Río , Noelia Ropero , Ramón Villagrasa , José Vivancos , Francisco Sanchez-Madrid , Arantzazu Alfranca\",\"doi\":\"10.1016/j.clicom.2023.02.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2.</p></div>\",\"PeriodicalId\":100269,\"journal\":{\"name\":\"Clinical Immunology Communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Immunology Communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S277261342300001X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S277261342300001X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
We analyzed immune response to SARS-CoV-2 vaccination by measuring specific IgG titers and T-cell reactivity to different SARS-CoV-2 peptides in multiple sclerosis patients taking different disease-modifying treatments. Of the 88 patients included, 72 developed any kind of immune response after vaccination. Although DMTs such as fingolimod and anti-CD20+ treatments prevented patients from developing a robust humoral response to the vaccine, most of them were still able to develop a cellular response, which could be crucial for long-term immunity. It is probably advisable that all MS patients take additional/booster doses to increase their humoral and/or cellular immune response to SARS-CoV-2.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
